| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hantavirus Infections | 33 | 2023 | 35 | 9.610 |
Why?
|
| Shrews | 23 | 2023 | 25 | 7.920 |
Why?
|
| Phylogeny | 74 | 2023 | 740 | 6.570 |
Why?
|
| Moles | 10 | 2023 | 10 | 4.660 |
Why?
|
| Genetic Variation | 31 | 2021 | 429 | 4.570 |
Why?
|
| RNA, Viral | 28 | 2023 | 317 | 2.870 |
Why?
|
| Chiroptera | 9 | 2020 | 23 | 2.660 |
Why?
|
| Evolution, Molecular | 14 | 2022 | 299 | 2.080 |
Why?
|
| Human T-lymphotropic virus 1 | 25 | 1999 | 35 | 1.830 |
Why?
|
| Arvicolinae | 18 | 2021 | 20 | 1.820 |
Why?
|
| Animals | 142 | 2023 | 16695 | 1.810 |
Why?
|
| Disease Reservoirs | 12 | 2019 | 24 | 1.540 |
Why?
|
| Genome, Viral | 16 | 2022 | 118 | 1.530 |
Why?
|
| HTLV-I Infections | 22 | 1995 | 33 | 1.370 |
Why?
|
| Molecular Sequence Data | 54 | 2014 | 1559 | 1.260 |
Why?
|
| Minority Groups | 7 | 2023 | 663 | 1.090 |
Why?
|
| Sequence Analysis, DNA | 22 | 2019 | 508 | 1.070 |
Why?
|
| Biomedical Research | 6 | 2025 | 467 | 1.040 |
Why?
|
| Rodent Diseases | 5 | 2014 | 13 | 0.990 |
Why?
|
| Bayes Theorem | 7 | 2023 | 121 | 0.970 |
Why?
|
| Genes, Viral | 14 | 2016 | 64 | 0.900 |
Why?
|
| Hemorrhagic Fever with Renal Syndrome | 20 | 2015 | 21 | 0.860 |
Why?
|
| Base Sequence | 35 | 2013 | 997 | 0.850 |
Why?
|
| Polymerase Chain Reaction | 31 | 2002 | 454 | 0.820 |
Why?
|
| Papilloma | 5 | 2001 | 17 | 0.820 |
Why?
|
| DNA, Viral | 27 | 2007 | 323 | 0.800 |
Why?
|
| Herpesviridae Infections | 6 | 2003 | 18 | 0.770 |
Why?
|
| Genotype | 12 | 2015 | 796 | 0.760 |
Why?
|
| Puumala virus | 3 | 2021 | 3 | 0.760 |
Why?
|
| Turtles | 6 | 2003 | 31 | 0.760 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 14 | 2020 | 649 | 0.730 |
Why?
|
| Humans | 164 | 2025 | 42163 | 0.690 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2020 | 22 | 0.670 |
Why?
|
| Vietnam | 9 | 2021 | 61 | 0.670 |
Why?
|
| Peromyscus | 8 | 1996 | 11 | 0.660 |
Why?
|
| Russia | 4 | 2022 | 28 | 0.650 |
Why?
|
| Cell Line | 21 | 2014 | 1416 | 0.640 |
Why?
|
| Poland | 6 | 2023 | 8 | 0.640 |
Why?
|
| Lung | 19 | 2019 | 484 | 0.640 |
Why?
|
| Antibodies, Viral | 26 | 2009 | 295 | 0.610 |
Why?
|
| Amino Acid Sequence | 24 | 2013 | 1188 | 0.580 |
Why?
|
| Paraparesis, Tropical Spastic | 9 | 2001 | 13 | 0.570 |
Why?
|
| HIV-1 | 10 | 2010 | 747 | 0.540 |
Why?
|
| Disaster Planning | 1 | 2018 | 58 | 0.540 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 22 | 1997 | 28 | 0.540 |
Why?
|
| JC Virus | 9 | 2007 | 23 | 0.530 |
Why?
|
| Disasters | 1 | 2018 | 74 | 0.530 |
Why?
|
| Cyclonic Storms | 1 | 2018 | 75 | 0.530 |
Why?
|
| RNA Viruses | 11 | 2019 | 22 | 0.530 |
Why?
|
| Hotlines | 1 | 2017 | 16 | 0.520 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2017 | 14 | 0.520 |
Why?
|
| Geography | 6 | 2021 | 107 | 0.490 |
Why?
|
| Hepatitis, Viral, Human | 4 | 2000 | 12 | 0.490 |
Why?
|
| Sequence Analysis, RNA | 2 | 2016 | 114 | 0.480 |
Why?
|
| Cluster Analysis | 7 | 2014 | 206 | 0.450 |
Why?
|
| Universities | 1 | 2018 | 539 | 0.440 |
Why?
|
| DNA Virus Infections | 5 | 2002 | 16 | 0.430 |
Why?
|
| Skin Neoplasms | 3 | 2001 | 175 | 0.430 |
Why?
|
| Research | 3 | 2021 | 177 | 0.410 |
Why?
|
| HIV Infections | 9 | 2010 | 2535 | 0.410 |
Why?
|
| Gene Products, env | 9 | 1994 | 23 | 0.400 |
Why?
|
| Melanesia | 20 | 2005 | 22 | 0.380 |
Why?
|
| Seals, Earless | 2 | 2003 | 6 | 0.380 |
Why?
|
| Prevalence | 10 | 2015 | 1597 | 0.370 |
Why?
|
| Amyotrophic Lateral Sclerosis | 19 | 1998 | 55 | 0.370 |
Why?
|
| Herpesviridae | 2 | 2003 | 12 | 0.370 |
Why?
|
| Viruses | 2 | 2003 | 39 | 0.360 |
Why?
|
| Health Services Research | 2 | 2010 | 161 | 0.360 |
Why?
|
| Male | 74 | 2023 | 22779 | 0.350 |
Why?
|
| Research Personnel | 5 | 2025 | 191 | 0.350 |
Why?
|
| Flaviviridae | 3 | 2000 | 4 | 0.340 |
Why?
|
| Alphaherpesvirinae | 2 | 2001 | 2 | 0.340 |
Why?
|
| Genes, env | 8 | 1996 | 13 | 0.340 |
Why?
|
| DNA Primers | 9 | 2021 | 295 | 0.330 |
Why?
|
| Reassortant Viruses | 2 | 2020 | 11 | 0.330 |
Why?
|
| Female | 65 | 2023 | 24018 | 0.320 |
Why?
|
| Emigration and Immigration | 3 | 2002 | 85 | 0.320 |
Why?
|
| Japan | 6 | 2021 | 348 | 0.320 |
Why?
|
| Guam | 19 | 2023 | 83 | 0.310 |
Why?
|
| DNA, Mitochondrial | 5 | 2011 | 185 | 0.310 |
Why?
|
| Simian T-lymphotropic virus 1 | 5 | 1995 | 5 | 0.310 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 4 | 2003 | 25 | 0.310 |
Why?
|
| Education, Public Health Professional | 1 | 2009 | 19 | 0.300 |
Why?
|
| Rodentia | 6 | 2021 | 47 | 0.300 |
Why?
|
| Genetics, Population | 5 | 2005 | 118 | 0.300 |
Why?
|
| Cote d'Ivoire | 3 | 2014 | 7 | 0.290 |
Why?
|
| Siberia | 3 | 2015 | 4 | 0.290 |
Why?
|
| Mice | 32 | 2021 | 6490 | 0.290 |
Why?
|
| Receptors, CCR5 | 2 | 1999 | 64 | 0.280 |
Why?
|
| Murinae | 3 | 2021 | 4 | 0.280 |
Why?
|
| Sequence Deletion | 2 | 1999 | 92 | 0.280 |
Why?
|
| Host-Pathogen Interactions | 4 | 2018 | 203 | 0.280 |
Why?
|
| West Nile virus | 4 | 2014 | 74 | 0.280 |
Why?
|
| Torque teno virus | 3 | 2002 | 9 | 0.280 |
Why?
|
| United States | 14 | 2025 | 5072 | 0.280 |
Why?
|
| Sequence Homology, Amino Acid | 10 | 2009 | 271 | 0.280 |
Why?
|
| Virus Replication | 11 | 2014 | 318 | 0.270 |
Why?
|
| Dementia | 15 | 1998 | 155 | 0.270 |
Why?
|
| Florida | 2 | 2020 | 461 | 0.270 |
Why?
|
| Neurodegenerative Diseases | 2 | 2009 | 138 | 0.270 |
Why?
|
| Parkinson Disease | 17 | 1998 | 207 | 0.270 |
Why?
|
| Adult | 44 | 2023 | 13458 | 0.270 |
Why?
|
| Scrapie | 12 | 1993 | 14 | 0.260 |
Why?
|
| Immunoglobulin G | 6 | 1998 | 253 | 0.260 |
Why?
|
| Environmental Exposure | 2 | 2009 | 247 | 0.260 |
Why?
|
| Sequence Homology, Nucleic Acid | 12 | 2008 | 90 | 0.260 |
Why?
|
| North America | 2 | 2019 | 85 | 0.260 |
Why?
|
| Brain | 23 | 2015 | 1452 | 0.260 |
Why?
|
| HIV Seropositivity | 2 | 1998 | 196 | 0.250 |
Why?
|
| Middle Aged | 52 | 2020 | 11819 | 0.240 |
Why?
|
| Hungary | 2 | 2019 | 8 | 0.240 |
Why?
|
| Viral Proteins | 10 | 2011 | 196 | 0.230 |
Why?
|
| Blood Donors | 2 | 1998 | 20 | 0.230 |
Why?
|
| Interinstitutional Relations | 1 | 2025 | 51 | 0.230 |
Why?
|
| China | 4 | 2020 | 233 | 0.230 |
Why?
|
| Mental Health | 1 | 2009 | 363 | 0.230 |
Why?
|
| Papua New Guinea | 13 | 2001 | 21 | 0.220 |
Why?
|
| Viruses, Unclassified | 2 | 2021 | 3 | 0.220 |
Why?
|
| Mental Disorders | 1 | 2009 | 377 | 0.220 |
Why?
|
| Pacific Islands | 6 | 2009 | 121 | 0.220 |
Why?
|
| Africa | 6 | 2020 | 81 | 0.220 |
Why?
|
| HTLV-I Antibodies | 6 | 1994 | 7 | 0.220 |
Why?
|
| Hantaan virus | 4 | 2013 | 4 | 0.220 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 2014 | 115 | 0.220 |
Why?
|
| Immunity, Innate | 4 | 2014 | 168 | 0.220 |
Why?
|
| Spain | 2 | 2023 | 43 | 0.220 |
Why?
|
| Retroviridae Proteins, Oncogenic | 6 | 1994 | 27 | 0.210 |
Why?
|
| Maryland | 2 | 2021 | 61 | 0.210 |
Why?
|
| Fluorescent Antibody Technique | 18 | 1991 | 196 | 0.210 |
Why?
|
| Texas | 3 | 2018 | 428 | 0.210 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2003 | 28 | 0.200 |
Why?
|
| Ukraine | 1 | 2023 | 4 | 0.200 |
Why?
|
| RNA-Directed DNA Polymerase | 3 | 2001 | 17 | 0.200 |
Why?
|
| Cooperative Behavior | 1 | 2025 | 250 | 0.200 |
Why?
|
| Antigens, Viral | 9 | 2009 | 50 | 0.200 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2002 | 246 | 0.200 |
Why?
|
| Microscopy, Electron | 19 | 2000 | 209 | 0.200 |
Why?
|
| Sequence Homology | 4 | 2014 | 34 | 0.190 |
Why?
|
| Substance Abuse, Intravenous | 3 | 1999 | 128 | 0.190 |
Why?
|
| Endothelial Cells | 4 | 2013 | 324 | 0.190 |
Why?
|
| Minority Health | 2 | 2022 | 96 | 0.190 |
Why?
|
| Aluminum | 8 | 1991 | 39 | 0.190 |
Why?
|
| Hawaii | 4 | 2023 | 2004 | 0.190 |
Why?
|
| Antigens, CD19 | 1 | 2002 | 15 | 0.190 |
Why?
|
| Vero Cells | 7 | 2015 | 109 | 0.180 |
Why?
|
| Prions | 10 | 1997 | 23 | 0.180 |
Why?
|
| Madagascar | 1 | 2021 | 7 | 0.180 |
Why?
|
| Virus Integration | 1 | 2002 | 65 | 0.180 |
Why?
|
| Epitopes | 6 | 1995 | 155 | 0.180 |
Why?
|
| Chromosome Walking | 1 | 2001 | 2 | 0.180 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2021 | 25 | 0.170 |
Why?
|
| Coronavirus | 1 | 2020 | 9 | 0.170 |
Why?
|
| Polymorphism, Genetic | 4 | 2007 | 200 | 0.170 |
Why?
|
| Virginia | 1 | 2020 | 12 | 0.170 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2021 | 40 | 0.170 |
Why?
|
| Animal Diseases | 2 | 2000 | 4 | 0.170 |
Why?
|
| Asia | 3 | 2014 | 99 | 0.170 |
Why?
|
| Neutralization Tests | 8 | 2009 | 55 | 0.170 |
Why?
|
| Hepatitis C | 2 | 1999 | 138 | 0.170 |
Why?
|
| HTLV-II Infections | 4 | 1993 | 6 | 0.160 |
Why?
|
| Herpesvirus 1, Cercopithecine | 1 | 2000 | 2 | 0.160 |
Why?
|
| Viral Envelope Proteins | 7 | 2004 | 90 | 0.160 |
Why?
|
| Rats | 11 | 2021 | 3701 | 0.160 |
Why?
|
| Blotting, Western | 13 | 2014 | 884 | 0.150 |
Why?
|
| Myanmar | 1 | 2019 | 2 | 0.150 |
Why?
|
| Animals, Wild | 3 | 2020 | 24 | 0.150 |
Why?
|
| Macrophages | 6 | 2013 | 515 | 0.150 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1998 | 44 | 0.150 |
Why?
|
| Neurons | 12 | 2014 | 1246 | 0.150 |
Why?
|
| Korea | 5 | 2014 | 37 | 0.150 |
Why?
|
| Behavioral Research | 1 | 2019 | 41 | 0.150 |
Why?
|
| New Orleans | 1 | 2018 | 17 | 0.150 |
Why?
|
| Genetic Vectors | 3 | 2008 | 165 | 0.150 |
Why?
|
| Motor Neurons | 3 | 1991 | 88 | 0.140 |
Why?
|
| Hantavirus Pulmonary Syndrome | 2 | 1995 | 3 | 0.140 |
Why?
|
| Genes, nef | 1 | 1998 | 5 | 0.140 |
Why?
|
| Gene Products, nef | 1 | 1998 | 19 | 0.140 |
Why?
|
| Europe | 3 | 2018 | 114 | 0.140 |
Why?
|
| Sequence Alignment | 6 | 2010 | 273 | 0.140 |
Why?
|
| Leukemia, T-Cell | 2 | 1995 | 6 | 0.140 |
Why?
|
| Astrocytes | 6 | 2014 | 244 | 0.140 |
Why?
|
| Puerto Rico | 3 | 2018 | 1376 | 0.140 |
Why?
|
| Primates | 2 | 1995 | 38 | 0.140 |
Why?
|
| Sensitivity and Specificity | 7 | 2021 | 602 | 0.140 |
Why?
|
| Bunyaviridae | 3 | 1987 | 5 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2003 | 379 | 0.140 |
Why?
|
| Infant | 8 | 2002 | 1143 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 8 | 2003 | 456 | 0.130 |
Why?
|
| Nepal | 2 | 2020 | 18 | 0.130 |
Why?
|
| Pacific Ocean | 1 | 2017 | 13 | 0.130 |
Why?
|
| Child, Preschool | 9 | 2002 | 1516 | 0.130 |
Why?
|
| Biological Specimen Banks | 1 | 2017 | 28 | 0.130 |
Why?
|
| Hospitalization | 1 | 2020 | 482 | 0.130 |
Why?
|
| Cells, Cultured | 13 | 2012 | 1617 | 0.130 |
Why?
|
| Tissue Distribution | 3 | 2014 | 230 | 0.130 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 2 | 1994 | 8 | 0.130 |
Why?
|
| Sulfonamides | 3 | 1993 | 88 | 0.130 |
Why?
|
| Taiwan | 1 | 2016 | 21 | 0.120 |
Why?
|
| Child | 12 | 2003 | 3381 | 0.120 |
Why?
|
| Likelihood Functions | 1 | 2016 | 62 | 0.120 |
Why?
|
| Axons | 7 | 1999 | 116 | 0.120 |
Why?
|
| Deltaretrovirus Antibodies | 3 | 1992 | 3 | 0.120 |
Why?
|
| Gene Products, gag | 2 | 1994 | 11 | 0.120 |
Why?
|
| Species Specificity | 9 | 2006 | 279 | 0.120 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1992 | 52 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2017 | 336 | 0.120 |
Why?
|
| Jews | 1 | 1995 | 6 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 744 | 0.120 |
Why?
|
| Nervous System Diseases | 6 | 1991 | 76 | 0.120 |
Why?
|
| Hominidae | 2 | 1995 | 12 | 0.120 |
Why?
|
| Virulence | 4 | 2007 | 238 | 0.120 |
Why?
|
| Endoplasmic Reticulum | 2 | 2014 | 108 | 0.120 |
Why?
|
| Cytopathogenic Effect, Viral | 5 | 2008 | 14 | 0.110 |
Why?
|
| Plasticizers | 3 | 1993 | 7 | 0.110 |
Why?
|
| Mentors | 2 | 2023 | 143 | 0.110 |
Why?
|
| Kuru | 4 | 1996 | 4 | 0.110 |
Why?
|
| Nerve Degeneration | 4 | 1992 | 108 | 0.110 |
Why?
|
| Glycosaminoglycans | 2 | 1991 | 24 | 0.110 |
Why?
|
| Adolescent | 11 | 1999 | 5950 | 0.110 |
Why?
|
| Africa South of the Sahara | 1 | 2014 | 51 | 0.110 |
Why?
|
| Sigmodontinae | 1 | 2014 | 2 | 0.110 |
Why?
|
| Spinal Cord | 6 | 2001 | 109 | 0.110 |
Why?
|
| HTLV-I Antigens | 1 | 1993 | 1 | 0.110 |
Why?
|
| Age Factors | 8 | 2015 | 1139 | 0.110 |
Why?
|
| Viremia | 2 | 1999 | 44 | 0.110 |
Why?
|
| Inclusion Bodies, Viral | 3 | 1991 | 4 | 0.110 |
Why?
|
| Intercostal Muscles | 1 | 2013 | 1 | 0.100 |
Why?
|
| Guinea | 1 | 2013 | 3 | 0.100 |
Why?
|
| France | 1 | 2013 | 21 | 0.100 |
Why?
|
| India | 4 | 2020 | 105 | 0.100 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2014 | 51 | 0.100 |
Why?
|
| History, 20th Century | 2 | 2009 | 124 | 0.100 |
Why?
|
| Gene Expression Regulation | 3 | 2013 | 1066 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 680 | 0.100 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2004 | 229 | 0.100 |
Why?
|
| Heterozygote | 3 | 1999 | 107 | 0.100 |
Why?
|
| Protein Structure, Secondary | 2 | 2009 | 185 | 0.100 |
Why?
|
| Deltaretrovirus Antigens | 2 | 1992 | 2 | 0.100 |
Why?
|
| Cross-Cultural Comparison | 1 | 1992 | 109 | 0.100 |
Why?
|
| Cricetinae | 10 | 2015 | 241 | 0.100 |
Why?
|
| Occupational Diseases | 3 | 1996 | 53 | 0.090 |
Why?
|
| Neoplasms | 1 | 2003 | 1341 | 0.090 |
Why?
|
| Disease Models, Animal | 12 | 1999 | 1554 | 0.090 |
Why?
|
| Muscle Spasticity | 2 | 1991 | 3 | 0.090 |
Why?
|
| Calcium | 6 | 1986 | 487 | 0.090 |
Why?
|
| Brain Chemistry | 2 | 1991 | 140 | 0.090 |
Why?
|
| Genes, gag | 4 | 1995 | 5 | 0.090 |
Why?
|
| Genes, pol | 4 | 1995 | 15 | 0.090 |
Why?
|
| Nucleocapsid | 2 | 2004 | 12 | 0.090 |
Why?
|
| Dementia, Vascular | 1 | 1991 | 36 | 0.090 |
Why?
|
| Myelin Sheath | 8 | 1999 | 46 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2009 | 727 | 0.090 |
Why?
|
| Sequence Analysis | 2 | 2008 | 26 | 0.080 |
Why?
|
| Capsid Proteins | 2 | 2001 | 74 | 0.080 |
Why?
|
| Gene Amplification | 3 | 1996 | 23 | 0.080 |
Why?
|
| Bunyaviridae Infections | 2 | 1993 | 7 | 0.080 |
Why?
|
| Founder Effect | 1 | 2010 | 9 | 0.080 |
Why?
|
| Finland | 1 | 2009 | 15 | 0.080 |
Why?
|
| Aged | 20 | 2020 | 7982 | 0.080 |
Why?
|
| Demography | 1 | 2010 | 195 | 0.080 |
Why?
|
| Liver | 2 | 2015 | 503 | 0.080 |
Why?
|
| Transduction, Genetic | 2 | 2008 | 21 | 0.080 |
Why?
|
| Drug Users | 1 | 2010 | 51 | 0.080 |
Why?
|
| Oregon | 1 | 2009 | 64 | 0.080 |
Why?
|
| Australia | 4 | 2005 | 95 | 0.080 |
Why?
|
| Serotyping | 4 | 1994 | 37 | 0.080 |
Why?
|
| Muridae | 5 | 2000 | 5 | 0.080 |
Why?
|
| RNA, Messenger | 4 | 2008 | 1265 | 0.080 |
Why?
|
| Glial Fibrillary Acidic Protein | 4 | 1997 | 74 | 0.070 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2004 | 225 | 0.070 |
Why?
|
| Mesocricetus | 9 | 2015 | 56 | 0.070 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2009 | 160 | 0.070 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 2803 | 0.070 |
Why?
|
| Adenoviridae | 1 | 2008 | 62 | 0.070 |
Why?
|
| Seasons | 1 | 2009 | 133 | 0.070 |
Why?
|
| Amino Acid Motifs | 1 | 2008 | 94 | 0.070 |
Why?
|
| Encephalopathy, Bovine Spongiform | 3 | 1993 | 3 | 0.070 |
Why?
|
| Moloney murine leukemia virus | 1 | 2008 | 7 | 0.070 |
Why?
|
| Hepacivirus | 2 | 1999 | 73 | 0.070 |
Why?
|
| Selenium | 2 | 2008 | 150 | 0.070 |
Why?
|
| Health Status Disparities | 2 | 2019 | 705 | 0.070 |
Why?
|
| Recombination, Genetic | 1 | 2008 | 96 | 0.070 |
Why?
|
| Metacarpus | 3 | 1989 | 4 | 0.070 |
Why?
|
| Immunohistochemistry | 7 | 1996 | 928 | 0.070 |
Why?
|
| Republic of Korea | 3 | 2013 | 133 | 0.070 |
Why?
|
| Proteinuria | 1 | 1988 | 55 | 0.070 |
Why?
|
| Infant, Newborn | 4 | 2000 | 960 | 0.070 |
Why?
|
| Deer | 3 | 1993 | 16 | 0.070 |
Why?
|
| Templates, Genetic | 2 | 2001 | 24 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2013 | 501 | 0.070 |
Why?
|
| Mutation | 4 | 2000 | 1169 | 0.070 |
Why?
|
| Bone and Bones | 2 | 1989 | 115 | 0.070 |
Why?
|
| West Nile Fever | 1 | 2008 | 64 | 0.070 |
Why?
|
| Gerstmann-Straussler-Scheinker Disease | 3 | 1996 | 3 | 0.070 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2007 | 15 | 0.070 |
Why?
|
| Molecular Epidemiology | 2 | 2020 | 58 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2013 | 683 | 0.070 |
Why?
|
| T-Lymphocytes | 5 | 1995 | 378 | 0.060 |
Why?
|
| Neurofibrils | 6 | 1999 | 23 | 0.060 |
Why?
|
| Risk Factors | 4 | 2020 | 3942 | 0.060 |
Why?
|
| Meningoencephalitis | 4 | 2015 | 14 | 0.060 |
Why?
|
| Pakistan | 2 | 2020 | 20 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2008 | 189 | 0.060 |
Why?
|
| Defective Viruses | 1 | 2006 | 10 | 0.060 |
Why?
|
| Lentivirus | 1 | 2006 | 24 | 0.060 |
Why?
|
| Interferons | 1 | 2005 | 37 | 0.060 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 436 | 0.060 |
Why?
|
| Escherichia coli | 2 | 2008 | 461 | 0.060 |
Why?
|
| Alzheimer Disease | 5 | 1998 | 972 | 0.060 |
Why?
|
| Cross Reactions | 5 | 2006 | 86 | 0.060 |
Why?
|
| Yugoslavia | 3 | 2002 | 3 | 0.060 |
Why?
|
| DNA, Complementary | 3 | 2007 | 195 | 0.060 |
Why?
|
| Risk-Taking | 2 | 1999 | 456 | 0.060 |
Why?
|
| Zoonoses | 3 | 1995 | 20 | 0.060 |
Why?
|
| Genes, pX | 2 | 1995 | 3 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 4 | 2000 | 506 | 0.060 |
Why?
|
| Viral Structural Proteins | 2 | 1995 | 17 | 0.050 |
Why?
|
| HIV Seroprevalence | 2 | 1996 | 11 | 0.050 |
Why?
|
| Cell Line, Tumor | 5 | 2014 | 2598 | 0.050 |
Why?
|
| Culicidae | 1 | 2004 | 26 | 0.050 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 573 | 0.050 |
Why?
|
| New Guinea | 3 | 2005 | 5 | 0.050 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2003 | 10 | 0.050 |
Why?
|
| Acidosis, Lactic | 1 | 2003 | 6 | 0.050 |
Why?
|
| Hippocampus | 6 | 1998 | 591 | 0.050 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2003 | 1 | 0.050 |
Why?
|
| Salicylic Acid | 1 | 2003 | 6 | 0.050 |
Why?
|
| Calcitriol | 1 | 1984 | 32 | 0.050 |
Why?
|
| Pan troglodytes | 5 | 1988 | 21 | 0.050 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 2 | 2007 | 7 | 0.050 |
Why?
|
| Cloning, Molecular | 3 | 2000 | 318 | 0.050 |
Why?
|
| Neurotoxins | 2 | 1994 | 55 | 0.050 |
Why?
|
| Indians, South American | 2 | 1993 | 9 | 0.050 |
Why?
|
| Tumor Virus Infections | 1 | 2003 | 22 | 0.050 |
Why?
|
| Prion Diseases | 2 | 1993 | 9 | 0.050 |
Why?
|
| Capsid | 2 | 2001 | 64 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2003 | 16 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2003 | 84 | 0.050 |
Why?
|
| Genes | 2 | 2001 | 56 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2003 | 92 | 0.050 |
Why?
|
| Proteins | 1 | 2005 | 383 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2004 | 276 | 0.050 |
Why?
|
| Chromosome Mapping | 3 | 1999 | 198 | 0.050 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2002 | 40 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 5 | 1998 | 111 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2003 | 95 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2022 | 106 | 0.050 |
Why?
|
| Ganglia, Spinal | 2 | 2001 | 41 | 0.050 |
Why?
|
| Neuromuscular Diseases | 1 | 1982 | 4 | 0.050 |
Why?
|
| Cattle Diseases | 2 | 1992 | 30 | 0.050 |
Why?
|
| Phenotype | 2 | 1997 | 774 | 0.050 |
Why?
|
| Program Development | 1 | 2023 | 237 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 2 | 2000 | 71 | 0.050 |
Why?
|
| DNA Topoisomerase IV | 1 | 2001 | 2 | 0.050 |
Why?
|
| DNA Gyrase | 1 | 2001 | 7 | 0.050 |
Why?
|
| Ofloxacin | 1 | 2001 | 7 | 0.050 |
Why?
|
| Respirovirus | 2 | 1980 | 3 | 0.050 |
Why?
|
| Minerals | 1 | 1982 | 52 | 0.050 |
Why?
|
| Restriction Mapping | 2 | 1991 | 45 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 2001 | 34 | 0.040 |
Why?
|
| Amyloid | 2 | 1993 | 66 | 0.040 |
Why?
|
| DNA Restriction Enzymes | 1 | 2001 | 13 | 0.040 |
Why?
|
| Feces | 2 | 2000 | 126 | 0.040 |
Why?
|
| Nucleocapsid Proteins | 1 | 2021 | 12 | 0.040 |
Why?
|
| Reverse Transcription | 1 | 2021 | 23 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2021 | 24 | 0.040 |
Why?
|
| Metals | 1 | 1982 | 113 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2001 | 88 | 0.040 |
Why?
|
| Parainfluenza Virus 1, Human | 1 | 1980 | 1 | 0.040 |
Why?
|
| Parainfluenza Virus 2, Human | 1 | 1980 | 1 | 0.040 |
Why?
|
| Paramyxoviridae Infections | 1 | 1980 | 1 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2001 | 74 | 0.040 |
Why?
|
| New York | 3 | 1995 | 88 | 0.040 |
Why?
|
| Hypnotics and Sedatives | 1 | 2020 | 27 | 0.040 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 1980 | 16 | 0.040 |
Why?
|
| Lymphatic Diseases | 1 | 1980 | 6 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 1980 | 63 | 0.040 |
Why?
|
| Parvoviridae Infections | 1 | 2000 | 2 | 0.040 |
Why?
|
| Parvovirus B19, Human | 1 | 2000 | 2 | 0.040 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2000 | 7 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 3 | 1993 | 382 | 0.040 |
Why?
|
| Cell Aggregation | 1 | 2000 | 18 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2020 | 236 | 0.040 |
Why?
|
| Belgium | 1 | 2020 | 4 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2023 | 733 | 0.040 |
Why?
|
| Muscle, Skeletal | 2 | 2001 | 308 | 0.040 |
Why?
|
| Neurites | 3 | 1995 | 40 | 0.040 |
Why?
|
| Herpesvirus 8, Human | 1 | 2000 | 29 | 0.040 |
Why?
|
| Karyotyping | 1 | 2000 | 44 | 0.040 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2000 | 26 | 0.040 |
Why?
|
| Incidence | 4 | 2002 | 1054 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2020 | 49 | 0.040 |
Why?
|
| Cryopreservation | 1 | 2000 | 33 | 0.040 |
Why?
|
| Neurofilament Proteins | 3 | 1995 | 30 | 0.040 |
Why?
|
| Influenza A virus | 2 | 1999 | 31 | 0.040 |
Why?
|
| Sex Factors | 4 | 1991 | 1008 | 0.040 |
Why?
|
| Diagnosis, Differential | 3 | 1998 | 236 | 0.040 |
Why?
|
| Rabbits | 4 | 1994 | 292 | 0.040 |
Why?
|
| Borna disease virus | 1 | 1999 | 1 | 0.040 |
Why?
|
| Coronavirus Infections | 1 | 2021 | 81 | 0.040 |
Why?
|
| Neurofibrillary Tangles | 3 | 1998 | 113 | 0.040 |
Why?
|
| Hepatitis Viruses | 1 | 1999 | 3 | 0.040 |
Why?
|
| Frontal Lobe | 1 | 1999 | 58 | 0.040 |
Why?
|
| Cell Survival | 2 | 2000 | 934 | 0.040 |
Why?
|
| DNA Viruses | 1 | 1999 | 14 | 0.040 |
Why?
|
| Serologic Tests | 2 | 2006 | 45 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 1998 | 26 | 0.040 |
Why?
|
| Sexually Transmitted Diseases, Viral | 1 | 1998 | 11 | 0.040 |
Why?
|
| Surface-Active Agents | 1 | 1999 | 44 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2019 | 89 | 0.040 |
Why?
|
| New England | 2 | 1995 | 18 | 0.040 |
Why?
|
| Gene Frequency | 1 | 1999 | 203 | 0.040 |
Why?
|
| Deltaretrovirus Infections | 2 | 1995 | 2 | 0.040 |
Why?
|
| Schizophrenia | 1 | 1999 | 91 | 0.040 |
Why?
|
| Bipolar Disorder | 1 | 1999 | 83 | 0.040 |
Why?
|
| Proviruses | 2 | 1995 | 35 | 0.040 |
Why?
|
| Toxoplasmosis, Cerebral | 1 | 1998 | 9 | 0.040 |
Why?
|
| Blotting, Southern | 2 | 2002 | 68 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2001 | 599 | 0.030 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 1998 | 53 | 0.030 |
Why?
|
| Influenza, Human | 1 | 1999 | 90 | 0.030 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 2 | 1994 | 17 | 0.030 |
Why?
|
| Alleles | 1 | 1999 | 352 | 0.030 |
Why?
|
| Optic Nerve | 2 | 1995 | 30 | 0.030 |
Why?
|
| Cultural Diversity | 1 | 2019 | 187 | 0.030 |
Why?
|
| Pneumonia, Viral | 1 | 1999 | 86 | 0.030 |
Why?
|
| Pyrones | 1 | 1996 | 11 | 0.030 |
Why?
|
| Microglia | 2 | 1998 | 204 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 1996 | 39 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2017 | 61 | 0.030 |
Why?
|
| Animals, Suckling | 2 | 2014 | 11 | 0.030 |
Why?
|
| Thailand | 1 | 1996 | 51 | 0.030 |
Why?
|
| Philippines | 1 | 2016 | 80 | 0.030 |
Why?
|
| Central Nervous System | 2 | 1989 | 150 | 0.030 |
Why?
|
| Inclusion Bodies | 2 | 2001 | 34 | 0.030 |
Why?
|
| Microwaves | 1 | 1996 | 27 | 0.030 |
Why?
|
| Transfection | 2 | 2008 | 526 | 0.030 |
Why?
|
| Viral Matrix Proteins | 1 | 1995 | 18 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 1996 | 134 | 0.030 |
Why?
|
| Retroviridae | 2 | 1987 | 25 | 0.030 |
Why?
|
| Blood-Brain Barrier | 2 | 2007 | 167 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1995 | 49 | 0.030 |
Why?
|
| Young Adult | 2 | 2020 | 4936 | 0.030 |
Why?
|
| Singapore | 3 | 1991 | 32 | 0.030 |
Why?
|
| Encephalitis, Viral | 1 | 1995 | 6 | 0.030 |
Why?
|
| History, Medieval | 1 | 1995 | 4 | 0.030 |
Why?
|
| Americas | 1 | 1995 | 5 | 0.030 |
Why?
|
| History, 16th Century | 1 | 1995 | 5 | 0.030 |
Why?
|
| Asia, Southeastern | 1 | 1995 | 12 | 0.030 |
Why?
|
| Antigenic Variation | 1 | 1995 | 8 | 0.030 |
Why?
|
| Monkey Diseases | 1 | 1995 | 6 | 0.030 |
Why?
|
| History, Ancient | 1 | 1995 | 15 | 0.030 |
Why?
|
| South America | 1 | 1995 | 22 | 0.030 |
Why?
|
| History, 19th Century | 1 | 1995 | 26 | 0.030 |
Why?
|
| Models, Genetic | 2 | 2006 | 181 | 0.030 |
Why?
|
| Brain Neoplasms | 2 | 1998 | 129 | 0.030 |
Why?
|
| Brazil | 1 | 1995 | 83 | 0.030 |
Why?
|
| Caribbean Region | 1 | 1995 | 75 | 0.030 |
Why?
|
| Iran | 1 | 1995 | 199 | 0.030 |
Why?
|
| Aluminum Compounds | 1 | 1994 | 10 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 1995 | 121 | 0.030 |
Why?
|
| Central Nervous System Viral Diseases | 1 | 2014 | 2 | 0.030 |
Why?
|
| Mice, Inbred ICR | 1 | 2014 | 43 | 0.030 |
Why?
|
| Antibody Formation | 2 | 1992 | 75 | 0.030 |
Why?
|
| Chlorides | 1 | 1994 | 59 | 0.030 |
Why?
|
| Histocytochemistry | 3 | 1991 | 47 | 0.030 |
Why?
|
| Herpesvirus 6, Human | 1 | 1994 | 5 | 0.030 |
Why?
|
| Macaca fascicularis | 3 | 1989 | 64 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2014 | 39 | 0.030 |
Why?
|
| Vesicular stomatitis Indiana virus | 1 | 1993 | 7 | 0.030 |
Why?
|
| Consensus Sequence | 1 | 1993 | 20 | 0.030 |
Why?
|
| Vacuoles | 4 | 1999 | 22 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2020 | 2485 | 0.030 |
Why?
|
| Cats | 1 | 1993 | 80 | 0.030 |
Why?
|
| Nucleotides | 1 | 1993 | 37 | 0.030 |
Why?
|
| Lepidoptera | 1 | 2013 | 10 | 0.030 |
Why?
|
| Carrier State | 1 | 1993 | 33 | 0.030 |
Why?
|
| Seoul virus | 1 | 2013 | 2 | 0.030 |
Why?
|
| Southwestern United States | 1 | 1993 | 47 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2013 | 33 | 0.030 |
Why?
|
| Amyloidosis | 2 | 1991 | 38 | 0.030 |
Why?
|
| Genetic Markers | 1 | 1994 | 146 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 1998 | 634 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 223 | 0.030 |
Why?
|
| Brain Diseases | 1 | 1993 | 31 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 1994 | 158 | 0.030 |
Why?
|
| Time Factors | 5 | 2005 | 1848 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 2 | 1991 | 95 | 0.020 |
Why?
|
| Homosexuality, Male | 1 | 1998 | 483 | 0.020 |
Why?
|
| Lymphocytes | 2 | 1999 | 124 | 0.020 |
Why?
|
| Amino Acids | 1 | 1993 | 150 | 0.020 |
Why?
|
| Base Composition | 1 | 1992 | 25 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1992 | 36 | 0.020 |
Why?
|
| Obesity | 1 | 2020 | 1131 | 0.020 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1992 | 50 | 0.020 |
Why?
|
| DNA, Single-Stranded | 1 | 1992 | 39 | 0.020 |
Why?
|
| Family | 1 | 1993 | 192 | 0.020 |
Why?
|
| Mesencephalon | 1 | 1992 | 42 | 0.020 |
Why?
|
| Immunocompetence | 2 | 1998 | 10 | 0.020 |
Why?
|
| Astrocytoma | 1 | 1992 | 16 | 0.020 |
Why?
|
| California | 1 | 1993 | 531 | 0.020 |
Why?
|
| Depression | 1 | 1999 | 837 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 1993 | 228 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 1991 | 7 | 0.020 |
Why?
|
| Cerebral Arteries | 1 | 1991 | 24 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 1991 | 35 | 0.020 |
Why?
|
| Atrophy | 1 | 1991 | 51 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 1991 | 58 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 1991 | 25 | 0.020 |
Why?
|
| Family Health | 1 | 1990 | 56 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 1992 | 303 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2013 | 426 | 0.020 |
Why?
|
| Nasal Mucosa | 2 | 1999 | 31 | 0.020 |
Why?
|
| Spinal Cord Diseases | 1 | 1989 | 5 | 0.020 |
Why?
|
| Visual Pathways | 1 | 1990 | 40 | 0.020 |
Why?
|
| Transients and Migrants | 1 | 2010 | 42 | 0.020 |
Why?
|
| Substantia Innominata | 1 | 1989 | 1 | 0.020 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1989 | 21 | 0.020 |
Why?
|
| Basal Ganglia | 1 | 1989 | 20 | 0.020 |
Why?
|
| Laboratory Infection | 1 | 1988 | 2 | 0.020 |
Why?
|
| Amino Acids, Diamino | 1 | 1988 | 2 | 0.020 |
Why?
|
| HTLV-II Antibodies | 3 | 1993 | 3 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1988 | 132 | 0.020 |
Why?
|
| Parkinson Disease, Secondary | 1 | 1988 | 11 | 0.020 |
Why?
|
| Peptides | 1 | 1992 | 357 | 0.020 |
Why?
|
| Genetic Techniques | 1 | 2008 | 14 | 0.020 |
Why?
|
| Brain Stem | 1 | 1989 | 51 | 0.020 |
Why?
|
| Seeds | 1 | 1988 | 46 | 0.020 |
Why?
|
| Virus Assembly | 1 | 2008 | 44 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2010 | 245 | 0.020 |
Why?
|
| Calcium, Dietary | 1 | 1989 | 64 | 0.020 |
Why?
|
| Culture Media | 1 | 2008 | 96 | 0.020 |
Why?
|
| Cercopithecidae | 1 | 1988 | 3 | 0.020 |
Why?
|
| Cebidae | 1 | 1988 | 4 | 0.020 |
Why?
|
| Electron Probe Microanalysis | 1 | 1988 | 13 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 1990 | 261 | 0.020 |
Why?
|
| PrP 27-30 Protein | 3 | 1993 | 3 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 1993 | 3077 | 0.020 |
Why?
|
| Plasmids | 1 | 2008 | 247 | 0.020 |
Why?
|
| AIDS-Related Complex | 1 | 1987 | 2 | 0.020 |
Why?
|
| Spumavirus | 1 | 1987 | 1 | 0.020 |
Why?
|
| Serotonin Antagonists | 1 | 2007 | 24 | 0.020 |
Why?
|
| Magnesium | 2 | 1985 | 93 | 0.020 |
Why?
|
| Manganese Poisoning | 2 | 1989 | 16 | 0.020 |
Why?
|
| Cattle | 3 | 1993 | 505 | 0.020 |
Why?
|
| Virion | 1 | 1987 | 73 | 0.020 |
Why?
|
| Nerve Fibers, Myelinated | 2 | 2001 | 16 | 0.020 |
Why?
|
| Silicon | 1 | 1986 | 17 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 1993 | 198 | 0.020 |
Why?
|
| HIV | 1 | 1987 | 100 | 0.020 |
Why?
|
| Microbial Collagenase | 1 | 1986 | 2 | 0.020 |
Why?
|
| Syndrome | 3 | 1998 | 73 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2006 | 40 | 0.020 |
Why?
|
| Apoptosis | 2 | 2008 | 1541 | 0.020 |
Why?
|
| Mitochondria | 2 | 2003 | 516 | 0.010 |
Why?
|
| Gerbillinae | 1 | 1985 | 2 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2006 | 207 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2006 | 238 | 0.010 |
Why?
|
| Neuroglia | 1 | 2005 | 131 | 0.010 |
Why?
|
| Glioblastoma | 1 | 2005 | 69 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 1985 | 67 | 0.010 |
Why?
|
| Deltaretrovirus | 1 | 1984 | 1 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 310 | 0.010 |
Why?
|
| Zoology | 1 | 1984 | 1 | 0.010 |
Why?
|
| Haplotypes | 1 | 2005 | 197 | 0.010 |
Why?
|
| Anopheles | 1 | 2004 | 20 | 0.010 |
Why?
|
| Databases, Nucleic Acid | 1 | 2004 | 30 | 0.010 |
Why?
|
| Hydroxyproline | 1 | 1984 | 2 | 0.010 |
Why?
|
| Calcitonin | 1 | 1984 | 5 | 0.010 |
Why?
|
| Sweden | 1 | 1984 | 17 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1986 | 278 | 0.010 |
Why?
|
| Genome | 1 | 2005 | 149 | 0.010 |
Why?
|
| Anthropology, Physical | 1 | 1984 | 8 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 1984 | 40 | 0.010 |
Why?
|
| Aedes | 1 | 2004 | 42 | 0.010 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1984 | 36 | 0.010 |
Why?
|
| Levodopa | 1 | 1983 | 26 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 2003 | 53 | 0.010 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2003 | 56 | 0.010 |
Why?
|
| Skin | 2 | 1986 | 185 | 0.010 |
Why?
|
| Nucleosides | 1 | 2003 | 30 | 0.010 |
Why?
|
| Colombia | 2 | 1993 | 30 | 0.010 |
Why?
|
| Congo Red | 2 | 1993 | 4 | 0.010 |
Why?
|
| Phosphorus | 1 | 1984 | 65 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2003 | 221 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 233 | 0.010 |
Why?
|
| Blood Cells | 1 | 2002 | 8 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2003 | 51 | 0.010 |
Why?
|
| Lactic Acid | 1 | 2003 | 110 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2002 | 30 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2003 | 205 | 0.010 |
Why?
|
| Micronesia | 1 | 1983 | 87 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 156 | 0.010 |
Why?
|
| Graft vs Host Reaction | 1 | 1982 | 1 | 0.010 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 1982 | 3 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 1982 | 18 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2002 | 79 | 0.010 |
Why?
|
| Infant, Newborn, Diseases | 1 | 1982 | 22 | 0.010 |
Why?
|
| Graft Rejection | 1 | 1982 | 43 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2008 | 990 | 0.010 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2001 | 10 | 0.010 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2001 | 8 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 2 | 1999 | 686 | 0.010 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2001 | 8 | 0.010 |
Why?
|
| Gene Pool | 1 | 2001 | 2 | 0.010 |
Why?
|
| Indians, Central American | 1 | 2001 | 3 | 0.010 |
Why?
|
| Amygdala | 1 | 1982 | 125 | 0.010 |
Why?
|
| Kidney | 1 | 1984 | 363 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 2001 | 92 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1994 | 522 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2001 | 135 | 0.010 |
Why?
|
| Point Mutation | 1 | 2001 | 98 | 0.010 |
Why?
|
| HIV Antibodies | 2 | 1993 | 24 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 2 | 1996 | 301 | 0.010 |
Why?
|
| Antibodies, Heterophile | 1 | 1980 | 2 | 0.010 |
Why?
|
| Cell Transformation, Viral | 1 | 1980 | 22 | 0.010 |
Why?
|
| Mice, Inbred Strains | 2 | 1995 | 116 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2001 | 232 | 0.010 |
Why?
|
| Sheep | 1 | 1980 | 77 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2004 | 1058 | 0.010 |
Why?
|
| Genes, Duplicate | 1 | 2000 | 4 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 1980 | 39 | 0.010 |
Why?
|
| Replication Origin | 1 | 2000 | 15 | 0.010 |
Why?
|
| Tissue Preservation | 1 | 1980 | 7 | 0.010 |
Why?
|
| Polyarteritis Nodosa | 1 | 1980 | 4 | 0.010 |
Why?
|
| Copper | 1 | 1982 | 134 | 0.010 |
Why?
|
| Mast Cells | 1 | 2001 | 83 | 0.010 |
Why?
|
| Population Dynamics | 1 | 2000 | 47 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1980 | 73 | 0.010 |
Why?
|
| Cardiovascular System | 1 | 1980 | 37 | 0.010 |
Why?
|
| Thymus Gland | 1 | 1980 | 74 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2000 | 168 | 0.010 |
Why?
|
| Dendrites | 2 | 1989 | 57 | 0.010 |
Why?
|
| Terminal Repeat Sequences | 1 | 1999 | 8 | 0.010 |
Why?
|
| Lipofuscin | 1 | 1999 | 3 | 0.010 |
Why?
|
| Chile | 1 | 1999 | 6 | 0.010 |
Why?
|
| Myofibrils | 1 | 1999 | 12 | 0.010 |
Why?
|
| Glycogen | 1 | 1999 | 20 | 0.010 |
Why?
|
| Death | 1 | 1999 | 11 | 0.010 |
Why?
|
| Staining and Labeling | 2 | 1991 | 106 | 0.010 |
Why?
|
| Chick Embryo | 1 | 1999 | 77 | 0.010 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 1998 | 13 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 1998 | 24 | 0.010 |
Why?
|
| Administration, Intranasal | 1 | 1999 | 89 | 0.010 |
Why?
|
| Quality of Life | 1 | 1983 | 599 | 0.010 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 1998 | 17 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2001 | 557 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1998 | 46 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1999 | 362 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 1998 | 59 | 0.010 |
Why?
|
| Apolipoproteins E | 1 | 1998 | 137 | 0.010 |
Why?
|
| Phagocytosis | 1 | 1998 | 83 | 0.010 |
Why?
|
| Cytoplasm | 2 | 1992 | 154 | 0.010 |
Why?
|
| tau Proteins | 1 | 1998 | 182 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1996 | 53 | 0.010 |
Why?
|
| Molecular Weight | 2 | 1994 | 168 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2001 | 580 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 1996 | 95 | 0.010 |
Why?
|
| Radiography | 2 | 1989 | 72 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1996 | 149 | 0.010 |
Why?
|
| Histological Techniques | 1 | 1996 | 12 | 0.010 |
Why?
|
| Chronic Disease | 2 | 1991 | 541 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2000 | 1729 | 0.010 |
Why?
|
| Regression Analysis | 2 | 1989 | 487 | 0.010 |
Why?
|
| Radioimmunoprecipitation Assay | 1 | 1995 | 1 | 0.010 |
Why?
|
| Indians, North American | 1 | 1997 | 179 | 0.010 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1995 | 7 | 0.010 |
Why?
|
| Papio | 1 | 1995 | 22 | 0.010 |
Why?
|
| Macaca | 1 | 1995 | 36 | 0.010 |
Why?
|
| Exanthema Subitum | 1 | 1994 | 1 | 0.010 |
Why?
|
| Slovakia | 1 | 1994 | 9 | 0.010 |
Why?
|
| HIV-2 | 1 | 1993 | 9 | 0.010 |
Why?
|
| Giant Cells | 1 | 1994 | 15 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 1994 | 97 | 0.010 |
Why?
|
| Up-Regulation | 1 | 1996 | 534 | 0.010 |
Why?
|
| Gene Expression | 1 | 1997 | 692 | 0.010 |
Why?
|
| Fetal Blood | 1 | 1993 | 48 | 0.010 |
Why?
|
| Mink | 1 | 1993 | 1 | 0.010 |
Why?
|
| Birefringence | 1 | 1993 | 2 | 0.010 |
Why?
|
| Saimiri | 1 | 1993 | 6 | 0.010 |
Why?
|
| Thymidine | 1 | 1993 | 15 | 0.010 |
Why?
|
| Tritium | 1 | 1993 | 51 | 0.010 |
Why?
|
| Ferrets | 1 | 1993 | 14 | 0.010 |
Why?
|
| Inflammation | 1 | 1999 | 729 | 0.010 |
Why?
|
| Contact Tracing | 1 | 1993 | 22 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1993 | 3 | 0.010 |
Why?
|
| Genes, Regulator | 1 | 1993 | 27 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1993 | 64 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 1993 | 81 | 0.010 |
Why?
|
| Haplorhini | 2 | 1984 | 23 | 0.010 |
Why?
|
| Gene Products, rex | 1 | 1992 | 1 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1993 | 181 | 0.010 |
Why?
|
| Cell Division | 1 | 1993 | 314 | 0.010 |
Why?
|
| DNA Replication | 1 | 1993 | 153 | 0.010 |
Why?
|
| Glioma | 1 | 1993 | 92 | 0.010 |
Why?
|
| Cell Death | 1 | 1993 | 277 | 0.010 |
Why?
|
| Ribosomes | 1 | 1992 | 34 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1992 | 62 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1991 | 21 | 0.010 |
Why?
|
| Kinetics | 1 | 1993 | 698 | 0.010 |
Why?
|
| Nucleic Acid Conformation | 1 | 1992 | 156 | 0.010 |
Why?
|
| Lethal Dose 50 | 1 | 1991 | 32 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1994 | 1112 | 0.010 |
Why?
|
| Alcian Blue | 1 | 1991 | 3 | 0.010 |
Why?
|
| Hospitals, General | 1 | 1991 | 5 | 0.010 |
Why?
|
| Immune Sera | 1 | 1991 | 56 | 0.010 |
Why?
|
| Organelles | 1 | 1991 | 21 | 0.010 |
Why?
|
| Down Syndrome | 1 | 1991 | 31 | 0.010 |
Why?
|
| Equipment Contamination | 1 | 1990 | 6 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1993 | 318 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1993 | 458 | 0.010 |
Why?
|
| Protein Conformation | 1 | 1991 | 420 | 0.010 |
Why?
|
| Anterior Chamber | 1 | 1990 | 14 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1991 | 350 | 0.010 |
Why?
|
| Synaptic Vesicles | 1 | 1989 | 31 | 0.000 |
Why?
|
| Heart | 1 | 1991 | 181 | 0.000 |
Why?
|
| Visual Cortex | 1 | 1990 | 65 | 0.000 |
Why?
|
| Intermediate Filament Proteins | 1 | 1989 | 16 | 0.000 |
Why?
|
| Oxidoreductases | 1 | 1969 | 79 | 0.000 |
Why?
|
| Intermediate Filaments | 1 | 1989 | 20 | 0.000 |
Why?
|
| Cell Count | 1 | 1989 | 140 | 0.000 |
Why?
|
| Models, Biological | 1 | 1992 | 711 | 0.000 |
Why?
|
| Synapses | 1 | 1990 | 184 | 0.000 |
Why?
|
| Paraplegia | 1 | 1988 | 2 | 0.000 |
Why?
|
| Disease Outbreaks | 1 | 1989 | 169 | 0.000 |
Why?
|
| Tropical Climate | 1 | 1988 | 23 | 0.000 |
Why?
|
| Analysis of Variance | 1 | 1989 | 574 | 0.000 |
Why?
|
| HIV Antigens | 1 | 1987 | 5 | 0.000 |
Why?
|
| Virus Cultivation | 1 | 1987 | 7 | 0.000 |
Why?
|
| Flavonoids | 1 | 1988 | 94 | 0.000 |
Why?
|
| Bacteria | 1 | 1969 | 285 | 0.000 |
Why?
|
| Disease Susceptibility | 1 | 1987 | 101 | 0.000 |
Why?
|
| Phenylmercuric Acetate | 1 | 1986 | 2 | 0.000 |
Why?
|
| Longitudinal Studies | 1 | 1989 | 1020 | 0.000 |
Why?
|
| Antigen-Antibody Complex | 1 | 1986 | 20 | 0.000 |
Why?
|
| Pancreas | 1 | 1986 | 45 | 0.000 |
Why?
|
| Organ Culture Techniques | 1 | 1986 | 102 | 0.000 |
Why?
|
| Immunization, Passive | 1 | 1985 | 19 | 0.000 |
Why?
|
| Rats, Inbred F344 | 1 | 1986 | 256 | 0.000 |
Why?
|
| Immunoglobulin M | 1 | 1985 | 87 | 0.000 |
Why?
|
| Enzyme Activation | 1 | 1986 | 462 | 0.000 |
Why?
|
| Immunity, Cellular | 1 | 1985 | 73 | 0.000 |
Why?
|
| Spleen | 1 | 1985 | 199 | 0.000 |
Why?
|
| Cytoskeleton | 1 | 1984 | 111 | 0.000 |
Why?
|
| Mice, Nude | 1 | 1985 | 403 | 0.000 |
Why?
|
| Sclerosis | 1 | 1982 | 5 | 0.000 |
Why?
|
| Spectrometry, X-Ray Emission | 1 | 1982 | 20 | 0.000 |
Why?
|
| Diet | 1 | 1989 | 810 | 0.000 |
Why?
|
| Blood Group Incompatibility | 1 | 1982 | 1 | 0.000 |
Why?
|
| Jaundice, Neonatal | 1 | 1982 | 1 | 0.000 |
Why?
|
| Transplantation Immunology | 1 | 1982 | 5 | 0.000 |
Why?
|
| ABO Blood-Group System | 1 | 1982 | 5 | 0.000 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 1982 | 6 | 0.000 |
Why?
|
| Hypothalamus | 1 | 1982 | 121 | 0.000 |
Why?
|
| Injections | 1 | 1980 | 40 | 0.000 |
Why?
|
| Cell Nucleus | 1 | 1982 | 383 | 0.000 |
Why?
|
| Freezing | 1 | 1980 | 17 | 0.000 |
Why?
|
| Herpesvirus 3, Human | 1 | 1980 | 13 | 0.000 |
Why?
|
| Aging | 1 | 1985 | 764 | 0.000 |
Why?
|
| Pregnancy | 1 | 1985 | 1737 | 0.000 |
Why?
|
| Cell Membrane | 1 | 1980 | 400 | 0.000 |
Why?
|
| Azotobacter | 1 | 1969 | 2 | 0.000 |
Why?
|
| Proteus | 1 | 1969 | 2 | 0.000 |
Why?
|
| Desulfovibrio | 1 | 1969 | 2 | 0.000 |
Why?
|
| Methods | 1 | 1969 | 14 | 0.000 |
Why?
|
| Chemistry | 1 | 1969 | 15 | 0.000 |
Why?
|
| Manometry | 1 | 1969 | 8 | 0.000 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1969 | 19 | 0.000 |
Why?
|
| Clostridium | 1 | 1969 | 24 | 0.000 |
Why?
|
| Chromatography, Gel | 1 | 1969 | 52 | 0.000 |
Why?
|
| Chemical Phenomena | 1 | 1969 | 56 | 0.000 |
Why?
|
| Solubility | 1 | 1969 | 134 | 0.000 |
Why?
|